Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7411425 | 0.98 | GAA (0.66) | GAAABL1KDM4ECA12CA1 | |
| SCHEMBL19328721 | 0.85 | GAA (0.72) | GAAABL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2701033 | 0.85 | GAA (0.61) | GAAABL1KDM4ECA12CA1 | |
| SCHEMBL7415528 | 0.85 | CA12 (0.55) | GAAABL1KDM4ECA12CA1 | |
| SCHEMBL2726967 | 0.83 | CA12 (0.53) | GAAABL1KDM4ECA12CA1 | |
| SCHEMBL30463099 | 0.83 | CA12 (0.53) | GAAABL1KDM4ECA12CA1 | |
| SCHEMBL1884944 | 0.83 | GAA (0.64) | GAAABL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11922587 | 0.82 | ABL1 (0.57) | GAAABL1KDM4ECA12CA1 | |
| SCHEMBL15797246 | 0.82 | GAA (0.68) | GAAABL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2897626 | 0.81 | GAA (0.62) | GAAABL1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858795-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010077915-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-08 | — | — | WO | disclosed |
| US-20090048299-A1 | or anticholinergic agents such as biphenyl-2-ylcarbamic acid 1-[2-({6-[(4-hydroxybenzylamino)methyl]pyridin-2-ylmethyl}carbamoyl)ethyl]piperidin-4-yl ester, used for the treatment of respiratory system disorders such as chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-02-19 | — | — | US | disclosed |
| US-7456199-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1723110-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005087735-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203139-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-5244907-A | Treatment of serotonin imbalance, increase in gastric motility, antiemetics, antiarrhythmia agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-09-14 | — | — | US | disclosed |
| US-5236931-A | Treating anxiety, psychosis, cognitive dysfunction, migrane, cluster headache, trigeminal neuralgia emesis and impaired gastric motility | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-08-17 | — | — | US | disclosed |
| US-5190953-A | 1-azabicyclo(3.2.1.)octan-5-ylmethyl- or 1-azabicyclo(3.3.1) nonan-5-ylmethyl derivatives of carboxamides, thiocarboxamides or esters, thioesters | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-02 | — | — | US | disclosed |
| US-5137895-A | Antiemetic, anxiolytic, gastric emptying and serotonin modulating activity | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-08-11 | — | — | US | disclosed |
| US-5063230-A | Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-11-05 | — | — | US | disclosed |
| WO-1990006113-A1 | SUBSTITUTED SATURATED AND UNSATURATED INDOLE QUINOLINE AND BENZAZEPINE CARBOXAMIDES AND THEIR USE AS PHARMACOLOGICAL AGENTS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1990-06-14 | — | — | WO | disclosed |
| US-4920219-A | Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048299-A1 | or anticholinergic agents such as biphenyl-2-ylcarbamic acid 1-[2-({6-[(4-hydroxybenzylamino)methyl]pyridin-2-ylmethyl}carbamoyl)ethyl]piperidin-4-yl ester, used for the treatment of respiratory system disorders such as chronic obstructive pulmonary disease and asthma | CHRM1, CHRM2, CHRM3 | GAA 3889/4885ABL1 3403/4885KDM4E 613/4885 |
| US-20050203139-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | GAA 4655/4885ABL1 3791/4885KDM4E 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.